KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Tax Provisions (2018 - 2026)

Moderna (MRNA) has disclosed Tax Provisions for 9 consecutive years, with $9.0 million as the latest value for Q1 2026.

  • For Q1 2026, Tax Provisions rose 28.57% year-over-year to $9.0 million; the TTM value through Mar 2026 reached $56.0 million, up 214.29%, while the annual FY2025 figure was $54.0 million, 217.39% up from the prior year.
  • Tax Provisions hit $9.0 million in Q1 2026 for Moderna, down from $27.0 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.7 billion in Q3 2023 and bottomed at -$384.0 million in Q1 2023.
  • Average Tax Provisions over 5 years is $125.1 million, with a median of $9.5 million recorded in 2024.
  • Year-over-year, Tax Provisions skyrocketed 1366.67% in 2022 and then plummeted 233.21% in 2023.
  • Moderna's Tax Provisions stood at $190.0 million in 2022, then plummeted by 177.37% to -$147.0 million in 2023, then skyrocketed by 56.46% to -$64.0 million in 2024, then skyrocketed by 142.19% to $27.0 million in 2025, then crashed by 66.67% to $9.0 million in 2026.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $9.0 million, $27.0 million, and $13.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.